{
  "id": 10863309,
  "title": "EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis",
  "url": "https://urgent.news/2026/09/30/eadv-2026-galdermas-new-data-show-sustained-improvements-with",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T05:04:40.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/eadv-2026-galdermas-new-data-show-sustained-improvements-with-nemluvio-nemolizumab-for-up-to-three-years-in-patients-with-moderate-to-severe-atopic-dermatitis"
  },
  "original_language": "en",
  "account": null,
  "summary": "New three-year ARCADIA long-term extension data demonstrate that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis1 The findings, to be shared at EADV 2026, show that up to 91% of patients achieved at least […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}